Project Research

David Berlove

Email: abqnko@r.postjobfree.com

Address: ** ******** ****

City: Newton

State: MA

Zip: 02458

Country: USA

Phone: 617-***-****

Skill Level: Experienced

Salary Range: $135,000

Willing to Relocate

Primary Skills/Experience:

See Resume

Educational Background:

See Resume

Job History / Details:

David J. Berlove, Ph.D.

18 Hazelton Road, Newton, Massachusetts 02459

617-***-**** abqnko@r.postjobfree.com

Summary

Scientific leader with extensive hands-on experience testing small

molecules in a wide range of animal models of disease including diabetes,

renal failure, metabolic disorders and multiple neurologic

indications. Ability to design, conduct and integrate in vivo, ex vivo and in vitro

studies for target assessment and compound evaluation. Skilled supervisor

and team builder in a matrix-management environment. Established

relationships with key opinion leaders in renal research. Excellent

presentation skills in a range of internal and external settings.

Successful project leader for preclinical research.

Education

Ph.D. in Neurobiology, University of Rochester, Rochester, NY

M.Sc. in Neuroscience and Biology, University of Rochester,

Rochester, NY

B.Sc. in Biology, University of Rochester, Rochester, NY

Experience

Genzyme Drug Discovery and Development (now a division of Sanofi), Waltham,

MA 1998-2012

A leading biotechnology company with small molecule, polymer, and protein

treatment platforms.

Senior Scientist II, Pharmacology (2001-2012)

Senior Scientist I, Pharmacology (1998-2001)

. Headed major renal discovery project team.

. Recruited, trained and led pharmacology research group.

. Designed and executed pharmacokinetic and tolerability studies.

. Developed rodent models of diabetes, renal failure and glomerulopathy.

. Identified and evaluated potential therapeutic targets for diabetes and

metabolic disorders

. Conducted long-term safety and toxicology studies of therapeutics in

rodents.

. Initiated internal and external development of colitis and mucositis

models.

. Evaluated internal and external opportunities in renal indications.

Cambridge NeuroScience, Cambridge, MA 1992-1998

A biotechnology company engaged in the discovery and development of

pharmacologic treatments for neurologic disorders.

Staff Scientist II, In Vivo Pharmacology (1995-1998)

Staff Scientist I, In Vivo Pharmacology (1992-1995)

. Developed and initiated cardiovascular safety screening program for new

compounds.

. Established rapid and reproducible behavioral screening paradigms.

. Designed and coordinated behavioral and safety studies at contract

research organizations.

. Established in-house models of inflammatory and neuropathic pain, and

external collaborations with leading analgesia laboratories.

. Initiated neuropathic pain project.

. Planned and executed pharmacokinetic studies of novel molecules.

. Developed excitotoxic disease models in collaboration with leading

academic researchers.

. Successfully introduced animal models of focal and global ischemia.

. Initiated internal anti-seizure screening program and research

collaboration with NIH.

. Set up and equipped In Vivo Pharmacology laboratory; recruited and

trained personnel.

. Chairman of Animal Care and Use Committee; ensured compliance with all

NIH, USDA and local regulations.

David J. Berlove, Ph.D. Page 2

Massachusetts General Hospital - Harvard Medical School - Department of

Neurology 1990-1992

Leading academic researchers in disease mechanism and drug discovery.

Research Fellow in CNS Growth Factor Research Laboratory

. Discovered protective effect of bFGF treatment in global cerebral

ischemia.

. Histologic studies of protein and growth factor immunoreactivity

following cerebral ischemia.

. Surveyed growth factor immunoreactivity following traumatic brain injury.

University of Rochester - Center for Brain Research 1984-1990

Private university with highly regarded research and training programs in

anatomy and neurobiology.

Graduate Student

. Intensive study of neuroanatomy, neuroimmunology and neuroendocrinology

including myelin structure and pathology.

. Analysis of peptide and receptor distribution in hypothalamus.

. Neuroscience Teaching Assistant.

University of Rochester School of Medicine - Cancer Center 1981-1983

Principal Technician - Animal Tumor Research Facility

. Serial passage in rats and mice of a variety of tumor types.

. Carcinogenicity studies with suspected tumor promoters and carcinogens.

Awards

AHA Stroke Research Fellowship

NIH SBIR Grant

Professional Affiliations

American Society for Nephrology

Specialized Training / Experience

. Recruitment, training and management of pharmacology research team.

. Project leadership.

. Rodent models of diabetes and renal disease.

. Animal models of focal and global ischemia.

. Statistical analysis and presentation.

. Stereotactic injection and surgery.

. Pharmacokinetic and pharmacodynamic studies.

. Behavioral pharmacology screens - Irwin test, rotarod, activity

monitoring.

. Knowledgeable in NIH and USDA animal use regulations and procedures.

. Extensive histology background including computerized image analysis.

. Proficient with a wide range of scientific and productivity software.

David J. Berlove, Ph.D.

18 Hazelton Road, Newton, Massachusetts 02459

617-***-**** abqnko@r.postjobfree.com

Addendum

Publications: Research Papers

1. Solution-phase, parallel synthesis and pharmacological evaluation of

acylguanidine derivatives as potential sodium channel blockers.

Padmanabhan, S., Thakker, P., Guo, J., Zhang, L., Moore, D., Perlman,

M.E., Kirk, C., Daly, D., Burke-Howie, K.J., Wolcott, T., Chari, S.,

Berlove, D., Fischer, J.B., Holt, W.F., Durant, G.J., McBurney, R.N. Bio

and Med Chem Letters 11 (24), pp. 3151-3155.

2. Synthesis and pharmacological evaluation of N,N'-diarylguanidines as

potent sodium channel blockers and anticonvulsant agents. Reddy L,

Wenhong F, Magar S, Perlman M, Yost E, Zhang L, Berlove D, Fischer J,

Burke-Howie K Wolcott T and G Durant. J. Med Chem 1998, 41:3298-3302.

3. Design, Synthesis and pharmacological evaluation of conformationally

constrained analogues of N,N'-diaryl- and N-aryl-N-aralkylguanidines as

potent inhibitors of neuronal Na+ channels. Maillard M, Perlman M, Amitay

O, Baxter D, Berlove D, Connaughton S, Fischer J, Guo J, Hu L, McBurney

R, Nagy P, Subbarao R, Yost E, Zhang L and G Durant. J. Med Chem 1998,

4:3048-3061.

4. Neuroprotective use-dependent blockers of Na+ and Ca2+ channels

controlling presynaptic release of glutamate. Goldin, S.M., Subbarao, K.,

Sharma, R., Knapp, A.G., Fischer, J.B., Daly, D., Durant, G.J., Reddy,

N.L., Hu, L.-Y., Magar, S., Perlman, M.E., Chen, J., Graham, S.H., Holt,

W.F., Berlove, D., Margolin, L.D. 1995 Ann NY Acad Sci Volume 765, Pages

210-229.

5. Pretreatment with intraventricular basic fibroblast growth factor (bFGF)

decreases infarct size following focal cerebral ischemia in rats. Koketsu

N, Berlove D, Moskowitz M, Kowall N, Caday C and S Finklestein. Ann.

Neurol. 1994; 35:451-457.

6. Basic fibroblast growth factor protects cerebrocortical neurons against

excitatory amino acid toxicity in vitro. Finklestein S, Kemmou A, Caday

C, Berlove D. Stroke, 1993:24 (suppl I): I141-143.

7. Polyubiquitin gene expression following cerebral ischemia. Caday, C.G.,

Sklar, R.M., Berlove, D.J., Kemmou, A., Brown Jr., R.H., Finklestein,

S.P. 1993 Ann NY Acad Sci Volume 679, Pages 188-194.

8. Growth factor expression after stroke. Finklestein S, Caday C, Kana M,

Berlove D, Hsu C, Moskowitz M. and M Klagsbrun. Stroke, 1990:21 (suppl

III): III122-124.

9. Immunocytochemistry of magnocellular neurons of supraoptic and

paraventricular nuclei of normal and Brattleboro rats with vasopressin

anti-idiotype antibody. Knigge K, Piekut D and D Berlove. Cell Tissue

Research 246: 509-513; 1986.

10. Staining of magnocellular neurons of the supraoptic and paraventricular

nuclei with vasopressin anti-idiotype antibody: a potential method for

receptor immunocytochemistry.Knigge K, Piekut D, Berlove D, Junig J and P

Melrose. Molecular Brain Research 2: 69-78; 1987.

11. Vasopressin receptor distribution in adrenalectomized rats using

vasopressin anti-idiotype. Peptides Berlove D and D Piekut. 10(4): 877-

881, 1989.

12. Immunocytochemistry of a vasopresssin receptor with anti-idiotype

antibody: inhibition of staining with a peptide encoded by an RNA that is

complementary to vasopressin mRNA. Knigge K, Piekut D and D Berlove.

Neuroscience Letters, 86: 269-271; 1988.

13. Co-localization of putative vasopressin receptors and vasopressinergic

neurons in rat hypothalamus. Berlove D and D Piekut. Current Opinions in

Biology, 1990.

Book Chapters

1. Goldin S, Subbarao K, Sharma R, Knapp A, Fischer J, Daly D, Durant G,

McBurney R, Reddy N, Magar S, Pearlman M, Chen Graham S, Holt W, Berlove

D and Margolin L. Neuroprotective use-dependent blockers of Na+ and Ca2+

channels controlling presynaptic release of glutamate. Annals of the New

York Academy of Sciences 1995, 765:210-229.

David J. Berlove, Ph.D. Page 2

2. Berlove D and S Finklestein. Growth factors and brain injury. In:

Growth Factors, Peptides, and Receptors, edited by T. Moody; in Growth

Factors, Peptides and Receptors. New York: Plenum Press 1993; 137-143.

3. Caday C, Sklar R, Berlove D, Kemmou A, Brown R and S Finklestein.

Polyubiquitin gene expression following cerebral ischemia. In:

Johannessen J ed. Markers of Neuronal Injury and Degeneration.New

York: Annals of the New York Academy of Sciences 1993, 679:188-194.

4. Piekut D, Knigge K, Berlove D, Junig J and P Melrose. Application of

anti-idiotype antibodies for studies on vasopressin and corticotropin-

releasing factor receptors. In: Membrane Proteins, edited by S. Goheen,

pp. 587-600. Bio-Rad Laboratories, Richmond, CA; 1987.

5. Knigge K, Piekut D, Abood L, Joseph S, Michael G, Xin L and D Berlove.

Immunocytochemistry of receptors using anti-idiotype antibody. In:

Methods in Enzymology - Anti-idiotypic Antibodies and Molecular Mimicry,

edited by J. Langone, pp. 212-221. Academic Press, San Diego, CA; 1989.

Patents

Co-inventor on nine US patents related to development of small molecule

therapeutics.

Abstracts

1. Effects of 1, 25 dihydroxyvitamin D3 on calcium and phosphorus

homeostasis in the mouse. David J. Berlove, Alexander Brezzani, Kelly

Keefe, Robert Sacchiero, Zhonglin Zhao. Society Nephrol Abstracts 2010:

SA-PO2139

2. 1, 25 dihydroxyvitamin D3 promotes medial vascular calcification in

uremic rat. Zhonglin Zhao, Alexander Brezzani, Lucy A. Phillips, Martin

Hanus, Robert Sacchiero, David J. Berlove. Society Nephrol Abstracts

2010: SA-PO2158

3. Severe uremia reduces intestinal NaPiIIb expression which is corrected

by vitamin D but inhibited by nicotinamide treatment. David Berlove,

Jennifer Strauss, Zhonglin Zhao, Alexander Brezzani, Katherine Roe, John

Leonard, Robert Sacchiero. Society Nephrol Abstracts 2008: SA-FC349

4. 24 hour urine P may be a poor indicator of efficacy for phosphate

binders when tested in rats using synthetic diets. Robert Sacchiero,

David Berlove, Alex Brezzani, Zhonglin Zhao, John Leonard. Society

Nephrol Abstracts 2008: PUB181

5. Comparison of sevelamer and lanthanum phosphate binding efficacy in the

rat. David J. Berlove, Peter J. Eworonsky, Steven Ledbetter. Society

Nephrol Abstracts 2005: SA-PO873

6. Lanthanum deposition in tissues of renal compromised rats fed lanthanum

carbonate for 28 days. Robert Sacchiero, David Berlove, Alexander

Brezzani, Martin Hanus, Eugene Zhorov, Steven Burke. Society Nephrol

Abstracts 2003: F-PO658.

7. Synthesis and structure-activity relationships of substituted N-aryl-

Naralkyl-guanidines as anti-seizure agents. Hu L, Durant G, Guo J,

Maillard M, Wolcott T and D Berlove. American Chemical Society Meeting

1997, Med Chem 32.

8. Synthesis and anti-seizure activity in the audiogenic DBA/2 mouse model.

Reddy N, Amitay O, Berlove D, Fan W, Fischer J, Magar S, Wolcott T, Yost

E and G Durant. American Chemical Society Meeting 1996, Med Chem 57.

9. Novel NMDA-receptor ion channel blockers potently reduce nociceptive

behavior in mouse formalin test. Berlove D, Amitay O, Hu L-Y, Magar S and

W Holt. American Pain Society Abstracts, 1996.

10. NMDA antagonists and glutamate release inhibitors suppress seizures in

the DBA/2 Mouse. Berlove D, Amitay O, Goldin S, Margolin L and W Holt.

Neuroscience Abstracts 1995, 770.13.

11. In Vitro Potency of Novel NMDA Antagonists Predicts In Vivo Protection

against Seizures and Neurotoxicity. Amitay O, Berlove D, Burke-Howie K,

Fischer J and W Holt. 1995, Behavioral Pharmacology 6(5-6):615.

12. Use-dependent block of 3H glutamate release from rat brain nerve

terminals. Subbarao K, D Berlove, G Durant, J Fischer, N Reddy, L Hu and

S Goldin. Neuroscience Abstracts 1994, 35.1.

13. Biphasic induction of basic fibroblast growth factor (bFGF) gene

expression following transient global ischemia. Caday C, Berlove D,

Kemmou A, Sklar R and S Finklestein. Ann Neurol 1993:251.

David J. Berlove, Ph.D. Page 5

14. Expression of glial growth factors in rat CNS implicates their

involvement in sensory and motor functions. Chen M, Danehy F, Mortin L,

Birmingham-McDonogh O, Berlove D, Gwynne D and M Marchionni. Neuroscience

Abstracts 1993, 109.13.

15. Identification by differential screening of heat shock protein-86

induced in gerbil hippocampus following transient global ischemia. Sklar

R, Caday C, Berlove D, Kemmou A, Brown R and S Finklestein.

Neuroscience Abstracts 1993, 676.12.

16. Basic fibroblast growth factor protects against delayed neuronal death

following global cerebral ischemia. Berlove D, Caday C, Kemmou A,

Boccalini P, Moskowitz M and S Finklestein. Neuroscience Abstracts 1991,

501.13.

17. Immunocytochemical study of peptide receptors in the central nervous

system. Berlove D, Michael G, Piekut D and K Knigge. New York Academy of

Sciences Symposium on Presynaptic Receptors. Extended abstract, 1990.

18. Staining of vasoporessinergic neurons in adrenalectomized rats using a

vasopressin anti-idiotype antibody. Berlove D, Piekut D, and K Knigge.

Neuroscience Abstracts 1988, 315.16.

19. Immunostaining of magnocellular neurons of the supraoptic and

paraventricular nuclei of rat hypothalamus with vasopressin anti-idiotype

antibody. Berlove D, Piekut D, and K Knigge. Neuroscience Abstracts

1986, 230.3.

Contact this candidate